IP Library Granted Patent US 6,967,203
Granted Patent B2
US 6,967,203 · App. 10/476,322 · Granted Nov 22, 2005

Use of pyridoindolone derivatives for preparing anticancer medicines

Assignee: Sanofi-Aventis
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,967,203
App. No.
10/476,322
Granted
Nov 22, 2005
Kind
B2
Abstract

The invention relates to a novel use of compounds of formula: for the preparation of medicinal products that are useful as anticancer agents.

Claims (64)

1. A method of inhibiting the proliferation of breast tumor cells which comprises administering to a patient in need of such inhibition an effective amount of a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group; or

R 1 and R 2 together form a (CH 2 ) 3 group;

r 3 represents either a phenyl group optionally substituted with a halogen atom or a methyl or methoxy group, or a thienyl group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 which comprises administering a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group; or

R 1 and R 2 together form a (CH 2 ) 3 group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

3. A method according to claim 1 which comprises administering a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group,

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1 wherein the compound is selected from:

6-chloro-1,9-dimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one;

3-(4-methoxyphenyl)-1,9dimethyl-1,9dihydro-2H-pyrido[2,3-b]indol-2-one;

1,6,9-trimethyl-3-(3-thienyl)1,9-dihydro-2H-pyrido[2,3-b]indol-2-one;

1,6,9-trimethyl-3-phenyl-1,9dihydro-2H-pyrido[2,3-b]indol-2-one; or

1,6dimethyl-3-phenyl-1,9dihydro-2H-pyrido[2,3-b]indol-2-one; or a pharmaceutically acceptable salt thereof.

5. A method according to claim 1 which comprises administering a compound of formula:

in which:

R 1 represents a methyl or ethyl group;

R 2 represents a methyl or ethyl group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

6. A method for treating breast cancer or breast tumors which comprises administering to a patient in need of such treatment an effective amount of a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group; or

R 1 and R 2 together form a (CH 2 ) 3 group;

r 3 represents either a phenyl group optionally substituted with a halogen atom or a methyl or methoxy group, or a thienyl group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

7. A method according to claim 6 which comprises administering a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group; or

R 1 and R 2 together form a (CH 2 ) 3 group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

8. A method according to claim 6 which comprises administering a compound of formula:

in which:

R 1 represents a hydrogen atom or a methyl or ethyl group;

R 2 represents a methyl or ethyl group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group; or a pharmaceutically acceptable salt thereof.

9. A method according to claim 6 which comprises administering a compound of formula:

in which:

R 1 represents methyl or ethyl group;

R 2 represents a methyl or ethyl group;

R 3 represents a hydrogen or halogen atom or a methyl or methoxy group;

R 4 represents a hydrogen or chlorine atom or a methyl or methoxy group.

10. A method according to claim 6 wherein the compound is selected from:

6-chloro-1,9dimethyl-3-phenyl-1,9dihydro-2H-pyrido[2,3-b]indol-2-one;

3-(4-methoxyphenyl)-1,9-dimethyl-1,9dihydro-2H-pyrido[2,3-b]indol-2-one;

1,6,9-trimethyl-3-(3-thienyl)-1,9dihydro-2H-pyrido[2,3-b]indol-2-one;

1,6,9-trimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; or

1,6-dimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; or a pharmaceutically acceptable salt thereof.

Assignments (3)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
CHANGE OF NAME Recorded Jul 22, 2005
From: SANOFI-SYNTHELABO
To: SANOFI-AVENTIS
Reel/Frame 016345/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2003
From: BOURIE, BERNARD; CASELLAS, PIERRE; DEROCQ, JEAN-MARIE
To: SANOFI-SYNTHELABO
Reel/Frame 015049/0789 →
Priority Claims (1)
FR 01 05843 · Apr 27, 2001 · national
Continuity (1)
Related Publication 20040122027A1 · Jun 24, 2004